what could happen if tt-034 is successful, page-30

not that simple Coolstocks. the interim safety data read will also show activity.

for sure it's only a safety dose, which is why they won't be able to report beyond the safety aspects. However, behind the closed doors they'll know very well whether the drug is showing effectiveness or not, but the HCV knockdown they are getting.

They'll have enough data from the NHP trials to know if this human trial is going the same way or not. And by they, i don't just mean benitec, but whoever the big pharma(s) is/or are that will undoubtedly be watching real closely.

So SP hit may not come from the final report on this trial, but rather a deal with a big pharma. All depends on how much they need to see before they are sufficiently satisfied to press the button.